Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

Muscle loss is a big concern for people on anti-obesity medications such as semaglutide. These ‘GLP-1 agonists’ mimic a ...

Viking Therapeutics (VKTX) surges 10% on renewed takeover speculation, with Pfizer rumored as a potential buyer.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

New obesity management medications, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), have shown high efficacy in clinical trials. Among GLP-1RAs, liraglutide and semaglutide have ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

As obesity rates rise, eligibility expands and curiosity about these medications grows ... a triple-hormone-receptor agonist combining GLP-1, GIP and glucagon receptors. Early trial data published ...

Feb. 12, 2024 – People with type 2 diabetes taking GLP-1 medicines may experience potentially blinding eye conditions as soon as the day after starting the drugs, and eye doctors are now asking ...

This medication also mimics GLP-1, in addition to ... polypeptide (or GIP), which plays a role in fat metabolism. Beyond treating type 2 diabetes and obesity, GLP-1 drugs are showing surprising ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...